Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. (NASDAQ: PHMD) is a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases. The company maintains its website at www.phathompharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Phathom Pharmaceuticals, Inc. does
In the company’s own words
Phathom Pharmaceuticals, Inc. (NASDAQ: PHMD) is a commercial-stage biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases. The company maintains its website at www.phathompharma.com.
Phathom's primary product portfolio consists of three FDA-approved medications containing vonoprazan, a potassium-competitive acid blocker, or PCAB. VOQUEZNA tablets are approved for healing and maintenance of erosive gastroesophageal reflux disease, or Erosive GERD, relief of heartburn associated with Non-Erosive GERD, and treatment of Helicobacter pylori infection in combination with antibiotics. VOQUEZNA DUAL PAK combines vonoprazan with amoxicillin, while VOQUEZNA TRIPLE PAK combines vonoprazan with amoxicillin and clarithromycin, both approved for H. pylori treatment. VOQUEZNA is the only PCAB currently approved for marketing in the United States. The company began U.S. commercialization in November 2023, with FDA approval for Non-Erosive GERD relief granted in July 2024. As of February 2026, over 1.1 million prescriptions have been filled since launch.
The company operates through a targeted national sales force of approximately 300 sales representatives, primarily focused on gastroenterologists and high-prescribing healthcare providers. Phathom has achieved broad commercial coverage with access for over 120 million covered lives, representing over eighty percent of U.S. commercial lives. All revenue is currently derived from U.S. sales of these three products.
Vonoprazan was originally developed by Takeda Pharmaceutical Company Limited and is marketed in multiple countries outside the United States. Phathom licensed U.S., European, and Canadian rights to vonoprazan from Takeda in 2019. The company benefits from ten-year new chemical entity exclusivity extending through May 2032 for all three VOQUEZNA products.
Beyond current commercialization efforts, Phathom initiated a Phase 2 clinical trial in the fourth quarter of 2025 evaluating vonoprazan for eosinophilic esophagitis treatment, with topline data anticipated in 2027. The company manufactures its products through third-party contract manufacturers including Evonik, Catalent, and Sandoz, maintaining personnel with manufacturing expertise to oversee supplier relationships.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1783183
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Phathom Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Phathom Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Phathom Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Phathom Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Phathom Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”